Twelve-month follow-up data from a clinical trial of OrbusNeich’s Genous stent has revealed that the device is safe and effective.

The Genous stent is an endothelial progenitor cell capture technology that enhances the natural healing of the vessel wall.

The multi-centre prospective clinical study, called e-HEALING, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention.

Target vessel failure occurred in 11.7% of patients over the age of 75, in 8.8% of patients between the ages of 65 and 74, and in 7% of patients younger than 65.

Secondary endpoint includes composite of cardiac death, myocardial infarction and the target lesion revascularization rate.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.